{"schema_version":"secwatch.filing_event.v1","accession":"0000926617-23-000093","form_type":"8-K","ticker":"AWHL","cik":"0000926617","company_name":"Aspira Women's Health Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.438430+00:00","generated_at":"2026-06-08T05:58:38.308246+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aspira Women's Health Q3 product revenue up 9% to $2.2M; cash burn down 56% to $3.3M","bullets":["Product revenue $2.2M (+9% YoY); OvaSuite volume 5,783 units (+5% YoY).","OvaWatch tests reached 1,015 in Q3, now nearly 20% of total OvaSuite volume.","Cash used in operations $3.3M, down 56% from $7.5M in Q3 2022; reiterated H2 2023 target $6-8M.","Gross margin improved to 59.0% from 55.8% YoY; R&D and SG&A expenses each down >50% YoY.","Raised $4.7M gross proceeds in registered direct offering; total cash $5.4M at Sep 30."],"urls":{"canonical":"https://secwatch.observer/filing/0000926617-23-000093","json":"https://secwatch.observer/filing/0000926617-23-000093.json","markdown":"https://secwatch.observer/filing/0000926617-23-000093.md","text":"https://secwatch.observer/filing/0000926617-23-000093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/926617/000092661723000093/0000926617-23-000093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/926617/000092661723000093/awh-20231113x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:58:38.308246+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"60aadfe58cfbe0e71870123e66995f090666a0dc","claim":"Aspira Women's Health Inc. reported the three and nine months ended September 30, 2023 results: revenue $2,217,000.","evidence_excerpt":"leading sales at Sema4Genomics and Sonic Reference Laboratory, Inc.  Third Quarter 2023 Financial Highlights Product revenue for the three months ended September 30, 2023, was $2,217,000, an increase of 9%, compared to $2,037,000 for the same period in 2022. The increase in revenue was primarily due to an increase in OvaSuite test volume compared to the prior year,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/926617/000092661723000093/0000926617-23-000093-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine months ended September 30, 2023"},{"label":"Revenue","value":"$2,217,000"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}